Human Oncology & Pathogenesis Program
The David Solit Lab
Research
Our research is based on the underlying hypothesis that the ability to inhibit an oncogenic pathway and block cancer growth will vary based on cell lineage and the complement of mutations within the tumor. To design rational therapeutic studies, we must define not only the spectrum of genetic changes within particular tumor types but also the mechanisms by which these alterations support tumor growth, survival, metastasis, and other hallmarks of cancer.
Research Projects
Featured News
Publications
People
David B. Solit, MD
Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
- Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials.
- MD, University of Pennsylvania
- solitd@mskcc.org
- Email Address
- View physician profile
- Physician profile
Members
- 646-422-4635 (for patient-related questions only)
- Office Phone
- University of Rochester
- BS, Massachusetts Institute of Technology
Lab Alumni
Lab Affiliations
Achievements
- Member, American Society for Clinical Investigation (2011)
- Louise and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2007)
- Kimmel Scholar, Sidney Kimmel Foundation for Cancer Research (2007)
- Career Development Award, American Society of Clinical Oncology (2002)
- Young Investigator Award, American Society of Clinical (2001)
Read more
- Doris Duke Translational Award, Doris Duke Foundation (2001)
- Clinical Scholars Research Fellow, National Institutes of Health (2000)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
-
Lab Head Email
-
For non-clinical issues only
-
For patient-related issues
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David B. Solit discloses the following relationships and financial interests:
-
American Association for Cancer Research
Provision of Services -
Apple Tree Life Sciences, Inc.
Provision of Services -
BridgeBio Inc.
Provision of Services -
Lilly Oncology
Provision of Services -
NovellusDx Ltd.
Ownership / Equity Interests; Provision of Services
-
Pfizer, Inc.
Provision of Services -
Scorpion Therapeutics, Inc.
Ownership / Equity Interests; Provision of Services -
Syros
Provision of Services -
Vividion Therapeutics
Ownership / Equity Interests; Provision of Services (uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.